Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Despite the Commodore 64 having been out of production for probably longer than many Hackaday readers have been alive, its ...
Abstract: Bipolar-CMOS-DMOS (BCD) technologies enable applications of high industrial interest, whereby high-voltage and highpower circuits are combined with high-density digital logic on a single die ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback